Valnoctamide

In Vitro

**SOLVENT & SOLUBILITY**

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>DMSO</td>
<td>6.9818 mL</td>
<td>34.9089 mL</td>
<td>69.8178 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>DMSO</td>
<td>1.3964 mL</td>
<td>6.9818 mL</td>
<td>13.9636 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>DMSO</td>
<td>0.6982 mL</td>
<td>3.4909 mL</td>
<td>6.9818 mL</td>
</tr>
</tbody>
</table>

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (17.45 mM); Clear solution

2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (17.45 mM); Clear solution

3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (17.45 mM); Clear solution

**BIOLOGICAL ACTIVITY**

**Description**

Valnoctamide (Valmethamide), a derivative of valproate, suppresses benzodiazepine-refractory status epilepticus. Valnoctamide (Valmethamide) acts directly on GABA<sub>A</sub> receptors<sup>[1]</sup>.

**IC₅₀ & Target**

GABA<sub>A</sub> receptor<sup>[1]</sup>
REFERENCES


Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898           Fax: 609-228-5909           E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA